How Much Does Target therapy for lung cancer Cost in Spain?
Target therapy for lung cancer in Spain typically costs from $4,500 to $13,000. Total expenses depend on the specific molecular profile, brand of medication, and the duration of the treatment course. In the United States, patients pay around $120,000 on average for similar therapies. Spain offers significant savings of approximately 93%. Protocols generally include genetic testing and oncological consultations.
- Diagnostic profiling: Biomarker and genetic testing often add 10-15% to the initial diagnostic budget.
- Treatment cycles: Private clinics generally price medications and administration starting from approximately $5,000 per dose.
- Main medical hubs: Premier oncology centers are primarily located in Madrid, Barcelona, and Pamplona.
- Hospital tiering: Pricing for international patients varies between top-ranked private hospitals and specialized oncology networks.
Bookimed Expert Insight: Choosing JCI-accredited centers like Clinica Universidad de Navarra or Hospital Ruber Internacional ensures access to advanced technologies. These institutions often use AI and robotic systems to enhance treatment precision. While per-dose costs are lower than in the US, international patients should budget for long-term oral therapy. Many Spanish centers, such as SJD Barcelona, maintain exceptional survival rates for complex oncological cases. Investing in a high-tier clinic often provides inclusive access to multidisciplinary teams and luxury private suites.
| Turkey | Austria | Spain | |
|---|---|---|---|
| Target therapy for lung cancer | from $5,000 | ≈ $9,000 | from $4,500 |
Your Benefits and Guarantees with Bookimed
Transparent Prices & Flexible Installments
No hidden fees – just official clinic prices. Pay at the clinic for Target therapy for lung cancer upon arrival and use a flexible installment plan if needed.
Verified Clinics & Doctors Only
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Target therapy for lung cancer and have the necessary licenses to serve international patients worldwide.
Free 24/7 Assistance
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Target therapy for lung cancer journey.

Your personal Bookimed medical coordinator
- Supports you at every stage
- Helps choose the right clinic and doctor
- Ensures quick and convenient access to information
Discover the Best Target therapy for lung cancer Clinics in Spain: 5 Verified Options and Prices
GenesisCare Clinics
Target therapy for lung cancer Overview in Spain
- Lobectomy - from $20,000The procedure involves removing a lung lobe, typically to treat conditions like lung cancer, improving patient health.
- Lung cancer surgery - from $37,800The procedure removes tumors in the lungs, aids with diagnosis, and generally alleviates symptoms and prolongs life.
- Lung segmentectomy - from $37,800This surgery removes lung segments harboring cancerous cells, protecting healthy tissue.
- Target therapy for lung cancer - from $4,500This therapy specifically attacks cancer cells, reducing damage to healthy ones. It"s less severe with notable efficacy.
Day 1 - Arrival
- Arrive at the medical facility.
- Complete necessary paperwork and registration procedures.
Day 2 - Pre-Operation
- Consultation with an oncologist and pulmonologist.
- Undergo physical examination and laboratory tests.
- Perform imaging studies like CT or MRI.
Day 3 - Preparing for Target Therapy
- Review of medical history and test results.
- Explanation of the target therapy procedure and its risks.
- Signing of consent forms.
Day 4 - Target Therapy
- Administration of target therapy drugs orally or through IV.
- The process lasts a few hours, no anesthesia required.
- The therapy targets specific genes and proteins of cancer cells.
Day 5 - Post-Operation
- Regular monitoring of vital signs and side effects.
- Stay in the clinic for observation for a day.
Week 1 - Rehabilitation
- Follow-up consultation with oncologist.
- Regular blood tests and imaging studies to monitor progress.
Week 2-4 - Rehabilitation
- Continuation of target therapy at home if advised by the doctor.
- Gradual return to work and daily activities.
Month 2-3 - Final Result
- Complete recovery and return to regular lifestyle.
- Regular check-ups to monitor cancer status.
Please note that the recovery process can vary depending on individual health conditions and how the body responds to the treatment.
- Bookimed deposit: $200 or €200.
- Clinic deposit: Pay a set percentage in advance.
Our Doctors
View all Doctors
Carlos Vergés Roger
Dr. Vergés specializes in ophthalmology with a focus on cataract and neurophysiological mechanisms of vision, backed by decades of research and clinical practice.
- Holds a PhD in Biology from Harvard University
- Director of the Ophthalmology Service at Dexéus University Hospital
- Recipient of the National Research Prize for his work on tear secretion
- Member of the International Society of Refractive Surgery and American Academy of Ophthalmology
Video Stories from Bookimed Patients
Reviews about Bookimed: Discover Patients' Insights
All reviews


Share this content
Anna Leonova
FAQ about Target therapy for lung cancer in Spain
Is biomarker testing mandatory before starting targeted therapy?
Biomarker testing is a clinical necessity before starting targeted therapy for lung cancer in Spain. While not a universal legal requirement for all patients, health authorities like the Spanish Agency of Medicines and Medical Devices (AEMPS) mandate these tests to approve and prescribe specific targeted drugs.
- Clinical standard: Testing identifies genomic variants like EGFR, ALK, and ROS1 to guide treatment selection.
- Treatment efficacy: Targeted oral therapies remain ineffective if the specific genetic mutation is not present.
- Toxicology prevention: Selecting biomarkers first prevents severe toxicities from less effective, aggressive alternative treatments.
- Spanish regulation: AEMPS guidelines require molecular profiling to authorize personalized medicine protocols in Spain.
Bookimed Expert Insight: Spanish oncology centers often integrate biomarker testing with advanced diagnostics like 3-Tesla MRI. Facilities such as Clinica Universidad de Navarra maintain European Society for Medical Oncology accreditation. This ensures testing protocols align with the latest international precision medicine standards for faster results. This integration is crucial because patients who wait for genetic results before starting therapy often see better long-term stability.
Patient Consensus: Patients emphasize that genetic testing is a non-negotiable step that provides a clear roadmap for personalized care. Many recommend explicitly asking your medical team for these results before consenting to standard chemotherapy.
What are the available targeted therapies for lung cancer in Spain?
Targeted lung cancer therapies in Spain utilize precision medicine to treat specific genetic mutations like EGFR, ALK, and ROS1. Leading oncology centers provide advanced inhibitors including Osimertinib and Selpercatinib, alongside innovative clinical trials for KRAS G12C and MYC mutations at JCI-accredited facilities.
- Biomarker testing: Essential molecular diagnostics identify driver mutations like EGFR, ALK, and ROS1 prior to treatment.
- Current medications: Targeted drugs include Osimertinib for EGFR and Selpercatinib for RET fusion-positive lung cancer.
- Innovative access: Clinical trials provide early access to KRAS G12C inhibitors and novel cancer vaccines.
- Specialized facilities: Major centers like Clinica Universidad de Navarra maintain European Society for Medical Oncology accreditation.
Bookimed Expert Insight: Spain presents a unique research-heavy landscape where patients access tomorrow's drugs today. Centers like Hospital Ruber Internacional and Navarra prioritize early-phase trials for MYC inhibitors like OMO-103. This clinical trial focus often bypasses standard reimbursement delays seen in the public sector.
Patient Consensus: Accuracy in initial genetic testing is the most critical step for success. Patients emphasize discussing drug resistance early and pursuing clinical trial options for the newest inhibitors.
Can I participate in clinical trials for targeted therapy in Spain?
You can participate in clinical trials for targeted therapy in Spain, which is a global leader in oncological research. Patients access cutting-edge biomarker-driven treatments and Phase 1 trials, including innovative lung cancer vaccines like BNT116, at JCI-accredited centers in Madrid, Barcelona, and Pamplona.
- Biomarker testing: Mandatory screenings for ALK, KRAS, and EGFR mutations determine trial eligibility.
- Expert centers: Clinica Universidad de Navarra is a leading JCI-accredited research hub.
- Advanced therapies: Programs include triple-drug combinations and molecular-guided experimental protocols.
- Trial resources: Search the EU Clinical Trials Register filtered by specific mutation types.
Bookimed Expert Insight: Spain is one of only 7 global sites for the BNT116 lung cancer vaccine trial. Clinics like Clinica Universidad de Navarra offer high-level integration between research and care. This allows patients with rare mutations to access Phase 1 experimental treatments long before they reach the general market.
Patient Consensus: Patients emphasize that early biomarker testing is vital. Many suggest looking beyond standard care into Phase 1 trials if you have specific resistance patterns or rare lung cancer mutations.
How does the National Health System (SNS) in Spain cover targeted therapies?
Spains National Health System (SNS) provides universal coverage for targeted therapies that are approved by the Ministry of Health. Patients access these treatments through public hospitals, where tax-funded care is free at delivery, though regional variations in availability and pharmaceutical co-payments may apply.
- Biomarker testing: Genetic testing for EGFR, ALK, or ROS1 is mandatory for treatment eligibility.
- Approval process: Therapies must pass strict Ministry of Health reimbursement reviews before full funding.
- Access pathway: Patients can request exceptional authorization for non-listed medicines via hospital therapeutic committees.
- Co-payment rules: Seniors pay 10% for pharmacy prescriptions, while most inpatient oncology drugs remain free.
Bookimed Expert Insight: While public coverage is universal, private centers like Clinica Universidad de Navarra or Hospital Ruber Internacional offer faster access to trials. Data shows these JCI-accredited facilities often implement digital imaging and molecular labs for specialized lung cancer care earlier than public regional centers.
Patient Consensus: Navigating health bureaucracy is easier when contacting patient associations for support. Most confirm that once a drug is on the national list, costs become negligible for low-income families.
What are the best hospitals or medical centers in Spain for lung cancer?
Spain hosts world-class oncology centers like Clinica Universidad de Navarra and Hospital Ruber Internacional, specializing in targeted lung cancer therapy. These Joint Commission International-accredited facilities offer advanced treatments including CyberKnife, immunotherapy, and molecular medicine within highly integrated research-led networks.
- Hospital Ruber Internacional: Madrid center utilizing CyberKnife, Gamma Knife, and Da Vinci Xi technology.
- Clinica Universidad de Navarra: European Society for Medical Oncology-accredited hospital leads in multidisciplinary research.
- GenesisCare Clinics: Specializes in advanced radiotherapy techniques like tomotherapy and precise brachytherapy.
- Diagnostic efficiency: Spanish oncologists prioritize rapid diagnostic protocols for urgent, life-threatening cases.
Bookimed Expert Insight: Spain’s oncology strength lies in research integration rather than single-center dominance. Clinics like Navarra maintain Joint Commission International status while serving 140,000 patients annually. This high volume ensures surgeons maintain precision in robotic and molecular treatments. Patients should target Madrid for the concentrated expertise found at Forbes-ranked institutions.
Patient Consensus: Patients value the speed of Spanish diagnostics for suspected lung cancer. Many recommend starting private treatment for immediate access, then transitioning to public care for long-term medication coverage.




















